Veerhealth Care Peer Comparison

NSE: NIYATILEAS | BSE: 511523

₹49.33

₹-0.52 (-1.04%)

As on 02-Sep-2026IST

Market cap

₹99 Cr

Revenue (TTM)

₹53 Cr

P/E Ratio

64.6

P/B Ratio

4.1

Div. Yield

0 %

Edit

	Veerhealth Care	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	99	35,235	29,452	17,414	15,090
Revenue (₹ Cr)	53	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	1.53	1,018.97	497.77	603.02	270.18
Net Margin (%)	2.87	10.47	20.72	22.63	23.29
RoE (%)	4.02	21.30	28.49	19.61	14.45
Price to Earnings	64.56	34.84	59.17	28.88	54.80
Price-To-Book	4.09	6.74	14.57	5.00	7.28

Income Statement (₹ Cr)

	Veerhealth Care	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	52.93	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	53.24	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	48.52	7,739.53	1,608.91	1,753.71	720.01
EBITDA	4.40	1,943.92	762.90	836.69	388.38
Depreciation	1.37	425.10	98.11	78.88	74.78
EBIT	3.03	1,518.82	664.79	757.81	313.60
Interest	0.54	148.45	26.33	5.43	0.26
Other Income	0.31	47.39	30.80	73.83	51.50
Exceptional Items	-0.31	-27.85	0.00	-25.66	-3.28
Profit before Tax	2.49	1,389.91	669.26	800.55	361.56
Provision for Tax	0.96	370.94	171.48	197.53	91.39
Profit after Tax	1.53	1,018.97	497.77	603.02	270.18

	Veerhealth Care	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	22.92	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.00	-7.58	0.00	0.00	2.51
Non-Current Liabilities	7.81	723.57	345.47	142.73	50.51
Current Liabilities	13.45	3,912.24	710.20	508.04	169.08
Total Liabilities	33.77	8,121.73	2,179.88	3,753.59	2,034.25

	Veerhealth Care	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	23.43	3,392.16	1,290.62	1,321.38	957.22
Current Assets	18.48	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	33.77	8,121.73	2,179.88	3,753.59	2,034.25
Total Debt*	4.91	731.70	136.01	0.00	0.38
Net Current Assets	5.03	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	--	393.94	8.97	4.82	3.91

	Veerhealth Care	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	-0.39	851.71	317.40	391.52	244.52
Cash Flow from Investing Activities	-8.20	-94.00	-298.16	-615.65	-159.99
Cash from Financing Activities	9.52	-813.96	24.96	-6.23	-98.77
Net Cash Inflow / Outflow	0.92	-56.25	44.21	-230.35	-14.24

	Veerhealth Care	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	3.15	22.49	23.45	25.50	29.62
ROE (%)	4.02	21.30	28.49	19.61	14.45
ROA (%)	3.92	11.42	19.48	16.31	12.66
EBIT Margin (%)	5.73	15.68	28.03	29.25	28.29
Net Margin (%)	2.87	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Veerhealth Care	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	177.22	18.36	78.33	7.93	-6.72
EBIT Growth (%)	642.22	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	200.79	32.39	182.61	21.66	-24.38
EPS Growth (%)	80.77	36.68	277.72	25.42	-21.99
Book Value Growth (%)	1.74	50.94	18.89	20.94	18.74

	Veerhealth Care	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	107.43	34.12	59.17	27.96	54.32
Price / Book Value	4.09	6.74	14.57	5.00	7.28
Dividend Yield (%)	0.00	0.19	0.15	0.35	0.52
EV/EBITDA	23.26	18.67	38.40	19.88	37.78
Market Cap (₹ Cr)	24.48	20,327.45	15,494.53	13,228.83	17,537.35

	Veerhealth Care	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.16	0.05	0.09	0.00	0.00
Short term debt to equity ratio	0.03	0.11	--	--	0.00
Current Ratio	1.37	1.43	2.09	5.21	7.39
Quick Ratio	1.04	0.82	1.37	3.85	5.46
Interest Coverage	5.61	10.36	26.41	148.49	1,386.30

	Veerhealth Care	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	18.41	26.46	22.82	41.42	41.52
Asset Turnover	1.36	1.09	0.93	0.70	0.52
Receivable days	78.02	87.83	85.17	132.12	132.49
Inventory Days	42.05	78.64	90.97	102.08	68.07
Payable days	76.44	174.97	137.94	133.54	123.94
Cash Conversion Cycle	43.62	-8.50	38.21	100.66	76.63

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.